342 related articles for article (PubMed ID: 27121714)
1. Beyond the Selective Inhibition of Histone Deacetylase 6.
Rodrigues DA; Thota S; Fraga CA
Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
Wagner FF; Olson DE; Gale JP; Kaya T; Weïwer M; Aidoud N; Thomas M; Davoine EL; Lemercier BC; Zhang YL; Holson EB
J Med Chem; 2013 Feb; 56(4):1772-6. PubMed ID: 23368884
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
Lin X; Chen W; Qiu Z; Guo L; Zhu W; Li W; Wang Z; Zhang W; Zhang Z; Rong Y; Zhang M; Yu L; Zhong S; Zhao R; Wu X; Wong JC; Tang G
J Med Chem; 2015 Mar; 58(6):2809-20. PubMed ID: 25734520
[TBL] [Abstract][Full Text] [Related]
6. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
De Vreese R; D'hooghe M
Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
[TBL] [Abstract][Full Text] [Related]
8. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
9. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors.
De Vreese R; Depetter Y; Verhaeghe T; Desmet T; Benoy V; Haeck W; Van Den Bosch L; D'hooghe M
Org Biomol Chem; 2016 Feb; 14(8):2537-49. PubMed ID: 26822143
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
[TBL] [Abstract][Full Text] [Related]
12. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
13. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.
De Vreese R; Van Steen N; Verhaeghe T; Desmet T; Bougarne N; De Bosscher K; Benoy V; Haeck W; Van Den Bosch L; D'hooghe M
Chem Commun (Camb); 2015 Jun; 51(48):9868-71. PubMed ID: 25994553
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
17. An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.
Shahidul Islam M; Nurul Islam M; Ashraful Hoque M; Nishino N; Kato T; Kim HJ; Ito A; Yoshida M
Bioorg Chem; 2015 Apr; 59():145-50. PubMed ID: 25797804
[TBL] [Abstract][Full Text] [Related]
18. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
Morgen M; Steimbach RR; Géraldy M; Hellweg L; Sehr P; Ridinger J; Witt O; Oehme I; Herbst-Gervasoni CJ; Osko JD; Porter NJ; Christianson DW; Gunkel N; Miller AK
ChemMedChem; 2020 Jul; 15(13):1163-1174. PubMed ID: 32348628
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
